

DT01 Rec'd PCT/PTO 19 JAN 2005

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#3

In re application of: Lu et al.

Application No. Currently unknown

Filed: Herewith

Confirmation No. Currently unknown

For: POLYPEPTIDE

Examiner: Not yet assigned

Art Unit: Not yet assigned

Attorney Reference No. 5585-69856-01

MAIL STOP PCT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(2)


Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicants respectfully request that these documents be listed as references cited on the issued patent.

Applicants filed this Information Disclosure Statement ("IDS") within three months of the date of entry of the national stage as set forth in § 1.491 in an international application. As a result, no fee should be required to file this IDS. However, if the Patent Office determines that a fee is required for Applicants to file this IDS, please charge any such fees, or credit overpayment, to Deposit Account No. 02-4550. A **duplicate** copy of this IDS is enclosed.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By 
Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

cc: Docketing

107522043

STO Rec'd PETP 19 JAN 2005

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Attorney Docket Number	5585-69856-01
Application Number	Not yet assigned
Filing Date	January 19, 2005
First Named Inventor	Lu
Art Unit	Not yet assigned
Examiner Name	Not yet assigned

U.S. PATENT DOCUMENTS

Copies of U.S. Patent documents do not need to be provided, unless requested by the Patent and Trademark Office. For patents, provide the patent number and the issue date. For published U.S. applications, provide the publication number and the publication date. For unpublished pending patent applications, provide the application number and the filing date.

Examiner's Initials*	Cite No. (optional)	Number	Publication Date	Name of Applicant or Patentee

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee

OTHER DOCUMENTS

Examiner's Initials*	Cite No. (optional)	
		Database NCBI 'Online!' Accession No. NP_006654 (2003).
		Database NCBI 'Online!' Accession No. NP_505955 (2003).
		Bergamaschi et al., "iASPP Oncoprotein is a Key Inhibitor of p53 Conserved From Worm to Human," <i>Nature Genet.</i> 33:162-167 (2003).
		Iwabuchi et al., "Stimulation of p53-Mediated Transcriptional Activation by the p53-Binding Proteins, 53BP1 and 53BP2," <i>J. Biol. Chem.</i> 273:26061-26068 (1998).
		Naumovski and Cleary, "The p53-Binding Protein 53BP2 Also Interacts with Bcl2 and Impedes Cell Cycle Progression at G ₂ /M," <i>Mol. Cell. Biol.</i> 16:3884-3892 (1996).
		Samuels-Lev et al., "ASPP Proteins Specifically Stimulate the Apoptotic Function of p53," <i>Mol. Cell</i> 8:781-794 (2001).
		Slee and Lu, "The ASPP Family: Deciding Between Life and Death After DNA Damage," <i>Toxicol. Lett.</i> 139:81-87 (2003).
		Takada et al., "RelA-Associated Inhibitor Blocks Transcription of Human Immunodeficiency Virus Type 1 by Inhibiting NF-κB and Sp1 Actions," <i>J. Virol.</i> 76:8019-8030 (2002).

EXAMINER SIGNATURE:	DATE CONSIDERED:
<p>* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.</p>	